Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mahar

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology in Drug Development|March 31, 2022
Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic FunctionKelly M Mahar, Bonnie C Shaddinger, Bandi Ramanjineyulu, et al.
The Journal of Sexual Medicine|August 14, 2013
Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose studyRajesh Shinghal, Allison Barnes, Kelly M Mahar, et al.
Clinical Pharmacology and Therapeutics|January 29, 2025
Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney DiseaseKelly M Mahar, Martijn van Noort, Paul van den Berg, et al.
Clinical Kidney Journal|October 5, 2019
Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposureStephen Caltabiano, Borut Cizman, Olivia Burns, et al.
Toxicologic Pathology|November 1, 2006
Pulmonary fibrosis and ferruginous bodies associated with exposure to synthetic fibersAndrew J Ghio, William Funkhouser, Christopher B Pugh, et al.
Frontiers in Pharmacology|May 4, 2013
Effects of Urotensin II Receptor Antagonist, GSK1440115, in AsthmaAlison Portnoy, Sanjay Kumar, David J Behm, et al.
Clinical Pharmacology and Therapeutics|November 1, 2025
Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With AnemiaKelly M Mahar, Shuying Yang, Brendan Johnson, et al.
Pathology|June 6, 2021
Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysisStuart J Gallagher, Teresa Bailey, Robert V Rawson, et al.
Clinical Pharmacology in Drug Development|July 4, 2019
A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With DyslipidemiaEric J Olson, Kelly M Mahar, Thomas F Haws, et al.
Vascular Medicine (London, England)|November 8, 2014
Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery diseaseEric Olson, Laura Demopoulos, Thomas F Haws, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology in Drug Development|March 31, 2022
Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic FunctionKelly M Mahar, Bonnie C Shaddinger, Bandi Ramanjineyulu, et al.
The Journal of Sexual Medicine|August 14, 2013
Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose studyRajesh Shinghal, Allison Barnes, Kelly M Mahar, et al.
Clinical Pharmacology and Therapeutics|January 29, 2025
Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney DiseaseKelly M Mahar, Martijn van Noort, Paul van den Berg, et al.
Clinical Kidney Journal|October 5, 2019
Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposureStephen Caltabiano, Borut Cizman, Olivia Burns, et al.
Toxicologic Pathology|November 1, 2006
Pulmonary fibrosis and ferruginous bodies associated with exposure to synthetic fibersAndrew J Ghio, William Funkhouser, Christopher B Pugh, et al.
Frontiers in Pharmacology|May 4, 2013
Effects of Urotensin II Receptor Antagonist, GSK1440115, in AsthmaAlison Portnoy, Sanjay Kumar, David J Behm, et al.
Clinical Pharmacology and Therapeutics|November 1, 2025
Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With AnemiaKelly M Mahar, Shuying Yang, Brendan Johnson, et al.
Pathology|June 6, 2021
Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysisStuart J Gallagher, Teresa Bailey, Robert V Rawson, et al.
Clinical Pharmacology in Drug Development|July 4, 2019
A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With DyslipidemiaEric J Olson, Kelly M Mahar, Thomas F Haws, et al.
Vascular Medicine (London, England)|November 8, 2014
Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery diseaseEric Olson, Laura Demopoulos, Thomas F Haws, et al.
Pageof 5